Search
Akero Therapeutics Inc
AKROAdd to Watchlist
54.650USD
0.0000.00%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
4.50BMarket Cap
LossP/E TTM
More Details of Akero Therapeutics Inc Company
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Akero Therapeutics Inc Info
Ticker SymbolAKRO
Company nameAkero Therapeutics Inc
IPO dateJun 20, 2019
CEOCheng (Andrew)
Number of employees63
Security typeOrdinary Share
Fiscal year-endJun 20
Address601 Gateway Boulevard, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504876488
Websitehttps://akerotx.com/
Ticker SymbolAKRO
IPO dateJun 20, 2019
CEOCheng (Andrew)
Company Executives of Akero Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-29.36%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+23.27%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-965.84%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-29.36%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+23.27%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-965.84%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Akero Therapeutics Inc?
The top five shareholders of Akero Therapeutics Inc are: Dr. Andrew Cheng, M.D., Ph.D.
How many institutions hold shares of Akero Therapeutics Inc (AKRO)?
As of 2026Q1, 499 institutions hold shares of Akero Therapeutics Inc, with a combined market value of approximately 491.95K, accounting for 0.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -100921305.00.
